On Tuesday 24 April 2024 at 10.00 a.m. the partners IRCCS Burlo Garofolo (LP), UNITS DSM (PP5) and Clonit (PP4) held a meeting at the offices of PP5 to agree on the next activities to be carried out for the implementation of WP 2 "Capitalisation of the feasibility study of a diagnostic for rare paediatric diseases".
The partners carried out the first transfer of the results obtained by Clonit, then called Experteam, during the CATTEDRA project in order to carry out an analysis and comparison between these and the results obtained in parallel by the DSM in internal projects.
The idea of the partnership is to improve on the results obtained by CATTEDRA by building a biosensor for evaluating JAK activity to improve the profiling of patients with rare immunological diseases in children.
Clonit will perform the transcriptomics tests for the confirmation of UNITS results.
The partners agreed to schedule a new meeting in September, also involving Univerzitetni klinični centre Ljubljana (PP2) for an update on their activities.
